Cullinan Therapeutics, Inc. (CGEM)
21.91
-0.42
(-1.88%)
USD |
NASDAQ |
Sep 03, 12:49
Cullinan Therapeutics Research and Development Expense (TTM) : 171.47M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 171.47M |
| March 31, 2026 | 188.07M |
| December 31, 2025 | 187.40M |
| September 30, 2025 | 184.95M |
| June 30, 2025 | 178.49M |
| March 31, 2025 | 153.72M |
| December 31, 2024 | 142.90M |
| September 30, 2024 | 137.26M |
| June 30, 2024 | 135.57M |
| March 31, 2024 | 126.71M |
| December 31, 2023 | 148.16M |
| September 30, 2023 | 134.63M |
| June 30, 2023 | 120.49M |
| Date | Value |
|---|---|
| March 31, 2023 | 119.51M |
| December 31, 2022 | 91.95M |
| September 30, 2022 | 91.50M |
| June 30, 2022 | 84.50M |
| March 31, 2022 | 69.87M |
| December 31, 2021 | 57.75M |
| September 30, 2021 | 53.50M |
| June 30, 2021 | 50.74M |
| March 31, 2021 | 51.45M |
| December 31, 2020 | 43.21M |
| September 30, 2020 | 30.38M |
| June 30, 2020 | 25.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Rallybio Corp. | 7.384M |
| MapLight Therapeutics, Inc. | 198.70M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |